UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.592

Sortiert nach

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer

Clinical cancer research, 2020-06, Vol.26 (11), p.2654-2663

2020

Link zum Volltext

Verfügbarkeit prüfen

Genomic Approaches to Understanding Response and Resistance to Immunotherapy

Clinical cancer research, 2016-12, Vol.22 (23), p.5642-5650

2016

Link zum Volltext

Verfügbarkeit prüfen

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

Clinical cancer research, 2016-05, Vol.22 (10), p.2386-2395

2016

Link zum Volltext

Verfügbarkeit prüfen

The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy

Clinical cancer research, 2018-02, Vol.24 (4), p.927-938

2018

Link zum Volltext

Verfügbarkeit prüfen

Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy

Clinical cancer research, 2021-02, Vol.27 (3), p.680-688

2021

Link zum Volltext

Verfügbarkeit prüfen

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

Clinical cancer research, 2016-12, Vol.22 (23), p.5651-5660

2016

Link zum Volltext

Verfügbarkeit prüfen

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

Clinical cancer research, 2016-05, Vol.22 (10), p.2351-2358

2016

Link zum Volltext

Verfügbarkeit prüfen

Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort

Clinical cancer research, 2019-04, Vol.25 (7), p.2254-2263

2019

Link zum Volltext

Verfügbarkeit prüfen

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

Clinical cancer research, 2016-12, Vol.22 (24), p.6010-6020

2016

Link zum Volltext

Verfügbarkeit prüfen

Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment

Clinical cancer research, 2019-02, Vol.25 (3), p.921-927

2019

Link zum Volltext

Verfügbarkeit prüfen

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

Clinical cancer research, 2016-12, Vol.22 (24), p.5983-5991

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer

Clinical cancer research, 2015-11, Vol.21 (22), p.5121-5130

2015

Link zum Volltext

Verfügbarkeit prüfen

Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer

Clinical cancer research, 2021-02, Vol.27 (3), p.759-774

2021

Link zum Volltext

Verfügbarkeit prüfen

Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment

Clinical cancer research, 2017-01, Vol.23 (1), p.21-25

2017

Link zum Volltext

Verfügbarkeit prüfen

TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer

Clinical cancer research, 2017-02, Vol.23 (3), p.636-648

2017

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer

Clinical cancer research, 2015-01, Vol.21 (1), p.166-174

2015

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Clinical cancer research, 2019-02, Vol.25 (4), p.1404-1414

2019

Link zum Volltext

Verfügbarkeit prüfen

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer

Clinical cancer research, 2015-10, Vol.21 (20), p.4686-4697

2015

Link zum Volltext

Verfügbarkeit prüfen

Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation

Clinical cancer research, 2017-11, Vol.23 (21), p.6567-6579

2017

Link zum Volltext

Verfügbarkeit prüfen

Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer

Clinical cancer research, 2016-12, Vol.22 (24), p.6204-6216

2016

Link zum Volltext

Verfügbarkeit prüfen

Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer

Clinical cancer research, 2017-08, Vol.23 (16), p.4578-4591

2017

Link zum Volltext

Verfügbarkeit prüfen

Contextual Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair

Clinical cancer research, 2010-09, Vol.16 (18), p.4553-4560

2010

Link zum Volltext

Verfügbarkeit prüfen

HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

Clinical cancer research, 2017-02, Vol.23 (3), p.677-686

2017

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer

Clinical cancer research, 2018-10, Vol.24 (19), p.4900-4912

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.592

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieClinical Cancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.592)
Mit Volltextzugriff
(1.578)

Publikationsform

Artikel
(1.592)

Sprache

Englisch
(1.592)
Japanisch
(529)

Erscheinungsjahr

n.n

Thema

Humans
(1.554)
Oncology
(1.516)
Life Sciences & Biomedicine
(1.508)
Science & Technology
(1.508)
Biological And Medical Sciences
(871)
Medical Sciences
(870)
Pharmacology. Drug Treatments
(829)
Antineoplastic Agents
(826)
Female
(773)
Drug Resistance, Neoplasm
(738)
Animals
(633)
Cell Line, Tumor
(592)
Cancer Research
(530)
Mice
(527)
Male
(516)
Drug Resistance, Neoplasm - Genetics
(501)
Middle Aged
(430)
Tumors
(421)
Aged
(375)
Antineoplastic Agents - Pharmacology
(371)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Free E-Journals
(1.592)
Single Journals
(1.592)

Zeitschrift / Serie

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer

Genomic Approaches to Understanding Response and Resistance to Immunotherapy

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy

Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer

Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer

Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment

TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer

Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer

Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation

Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer

Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer

Contextual Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair

HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer

Aktive Filter

Suchergebnisse filtern